Head and neck incidentalomas on positron emission tomographic scanning: Ignore or investigate?

Journal of Otolaryngology - Head and Neck Surgery

Volumn 40, Issue 5, 2011, Pages 384-390

  Al Hakami, Hadi A ^a   Makis, William ^a   Anand, Sumeet ^a   Mlynarek, Alex ^a   Black, Martin J ^a   Stern, Jerry ^a   Payne, Richard J ^a   Hier, Michael P ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

18F fluorodeoxyglucose positron emission tomography; Head and neck; Incidentaloma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK INCIDENTALOMA; HUMAN; INCIDENCE; INCIDENTALOMA; MALE; PAROTID GLAND; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; THYROID INCIDENTALOMA;

ADULT; AGED; AGED, 80 AND OVER; COOPERATIVE BEHAVIOR; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; INCIDENTAL FINDINGS; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; REFERRAL AND CONSULTATION; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 81855176295     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2011.100271     Document Type: Article

References (30)

1. Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol 2008;97:649-52, doi:10.1002/jso.21018. (Pubitemid 351812964)
2. Nakamoto Y, Tatsumi M, Hammoud D, et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234:879-85, doi:10.1148/radiol.2343030301. (Pubitemid 40250832)
3. Goyal P, Hsu JM, Kellman RM. Effect of 18F-fluorodeoxyglucose positron emission tomography on the management of patients with head and neck squamous cell carcinoma. J Otolaryngol Head Neck Surg 2008;37:694-9.
4. Rubello D, Nanni C, Castellucci P, et al. Does 18F-FDG PET/CT play a role in the differential.
5. Abouzied M, Crawford E, Nabi H, et al. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145-55.
6. Fogarty GB, Peters LJ, Stewart J, et al. The usefulness of fluorine18- labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck 2003;25:138-45, doi:10.1002/hed.10191. (Pubitemid 36133893)
7. Zimmer LA, Branstetter BF, Nayak JV, et al. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 2005;115:2029-34, doi:10.1097/01.MLG.0000181495. 94611.A6. (Pubitemid 44391669)
8. Heron DE, Andrade RS, Beriwal S, et al. PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol 2008;31:352-62, doi:10.1097/COC.0b013e318162f150.
9. Goerres GW, Schmid DT, Gratz KW, et al. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2003;39:547-51, doi:10.1016/S1368-8375(03) 00016-2.
10. Di Martino E, Nowak B, Hassan HA, et al. Diagnosis and staging of head and neck cancer - a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg 2000;126:1457-61.
11. Dahele M, Ung YC, Ehrlich L, et al. 18F-Fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre. J Otolaryngol Head Neck Surg 2008;37:712-7.
12. Kao C, Kwan AS, Kwan JK, et al. The role of 18F-fluorodeoxyglucose positron emission tomography in cancer screening: a preliminary report. Oncol Rep 2001;8:1145-8. (Pubitemid 33758185)
13. Yasuda S, Ide M, Fujii H, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83: 1607-11, doi:10.1054/bjoc.2000.1496. (Pubitemid 32001701)
14. Shen YY, Su CT, Chen GJ, et al. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 2003;50:217-21. (Pubitemid 36830094)
15. Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4, doi:10.1210/jc.2003-030465. (Pubitemid 37153705)
16. Strauss L, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991;32:623-48.
17. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery (St. Louis) 2001;130:941-6, doi:10.1067/msy.2001.118265. (Pubitemid 34014558)
18. Davis PW, Perrier ND, Adler L, et al. Incidental thyroid carcinoma identified by positron emission tomography scanning obtained for metastatic evaluation. Am Surg 2001;67:582-4. (Pubitemid 33738852)
19. Kim TY, Kim WB, Ryu JS, et al. 18F-Fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 2005;115:1074-8, doi:10.1097/01.MLG.0000163098.01398.79. (Pubitemid 40777005)
20. Chen YK, Ding HJ, Chen KT, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 2005;25:1421-6.
21. Yi JG, Marom EM, Munden RF, et al. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology 2005;236:271-5, doi:10.1148/radiol. 2361041007. (Pubitemid 40853322)
22. Choi JY, Lee KS, Kim HJ, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 2006;47:609-15.
23. Chu QD, Connor MS, Lilien DL, et al. Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 2006;72:272-5. (Pubitemid 351837710)
24. Bogsrud TV, Karantanis D, Nathan MA, et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007;28:373-81, doi:10.1097/MNM.0b013e3280964eae. (Pubitemid 46569170)
25. Are C, Hsu JF, Schoder H, et al. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 2007;141:239-47. (Pubitemid 44954295)
26. Kurata S, Ishibashi M, Hiromatsu Y, et al. Diffuse and diffuse-plusfocal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med 2007;21:325-30, doi:10.1007/s12149-007-0030-2. (Pubitemid 47283256)
27. King DL, Stack BC, Spring PM, et al. Incidence of thyroid carcinoma in fluorodeoxyglucose. Otolaryngol Head Neck Surg 2007;137:400-4.
28. Nam SY, Roh JL, Kim JS, et al. Focal uptake of 18 F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol 2007;67:135-9, doi:10.1111/j.1365-2265.2007.02850.x. (Pubitemid 46955453)
29. Chen W, Li G, Parsons M, et al. Clinical significance of incidental focal versus diffuse thyroid uptake on FDG-PET imaging. PET Clin 2008;2:321-9, doi:10.1016/j.cpet.2008.04.001.
30. Ramos CD, Chisin R, Yeung HW, et al. Incidental focal thyroid uptake on FDG positron mission tomographic scans may represent second primary tumor. Clin Nucl Med 2001;26:193-7, doi:10.1097/ 00003072-200103000-00002.